At the IGTP TODAY
The conference has been a meeting point and an opportunity to share strategies, knowledge and innovative projects that contribute to improving the health and quality of life of people affected by cancer. Pere Torán and Federico Fondelli, researchers affiliated with IGTP, have been recognised in the 2025 Research Awards.
_1762445197.png)
The event gathered more than 200 researchers, reviewing the Institute's scientific trajectory and looking ahead to the future of research and innovation at the Can Ruti Campus.
A project led by the Germans Trias i Pujol University Hospital and Research Institute has developed an AI-based facial recognition system, AcroFace, capable of detecting early signs of acromegaly with 93% accuracy. The researchers are now conducting a larger pilot study with 4,000 images from the general population to confirm these promising results and improve early diagnosis of this rare disease.
_1746530699_1761816045.jpg)
Researchers from the IGTP and HUGTiP have reviewed the current knowledge on the use of tear-derived extracellular vesicles as a source of biomarkers for both ocular and neurodegenerative diseases. They highlight the advantages of this approach compared with more invasive methods and discuss the remaining challenges for its clinical application.
A clinical trial involving 40 patients, led by IrsiCaixa and IGTP and conducted at HUGTiP, confirms that the RUTI® vaccine, owned by Archivel Farma, enhances the effectiveness of the current treatment for non-muscle-invasive bladder cancer.
The combination of the drug nivolumab with chemotherapy improves survival in patients with high-risk head and neck cancer and could become the new standard treatment, according to the results of an international trial led by professionals from ICO, IGTP and IDIBELL.
A study coordinated from Badalona by IrsiCaixa, the Catalan Institute of Oncology and the Germans Trias i Pujol Research Institute (within the CARE programme) has identified KIMA, a genomic signature that makes it possible to anticipate which patients with HR+/HER2- breast cancer will respond less well to CDK4/6 inhibitors. The finding, published in the journal Clinical and Translational Medicine, may help personalize therapies and design new combinations.
The "la Caixa" Foundation has announced the results of the 2025 call for proposals for its CaixaImpulse program, through which it supports 31 biomedical projects from research centres, hospitals and universities in Spain and Portugal. A project coordinated by IIS IGTP led by Ana Piqueras (HUGTiP) has been selected in the call to continue with the development and implementation of a medical device to find and remove cancer cells more accurately during surgery.
On 18 September, around thirty people involved in the Innomed program visited the Werfen facilities in Lliçà d'Amunt (the Immunoassay Technology Center). The meeting provided an opportunity to learn about the company's strategic areas and to establish contacts for exploring possible collaborations.
The report, available in its extended format and in summary versions, compiles the institution's activity during 2024 and reflects its growth and consolidation.
